MIRM — Mirum Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.23bn
- $1.25bn
- $186.37m
- 46
- 14
- 50
- 30
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 19.1 | 77.1 | 186 |
Cost of Revenue | |||||
Gross Profit | — | — | 17.2 | 64.7 | 139 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 54.7 | 104 | 84.6 | 208 | 345 |
Operating Profit | -54.7 | -104 | -65.4 | -131 | -158 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -52.5 | -103 | -84 | -142 | -162 |
Provision for Income Taxes | |||||
Net Income After Taxes | -52.6 | -103 | -84 | -136 | -163 |
Net Income Before Extraordinary Items | |||||
Net Income | -52.6 | -103 | -84 | -136 | -163 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -52.6 | -103 | -84 | -136 | -163 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.28 | -4.09 | -5.09 | -4.01 | -3.22 |